Avalon Trust Co Purchases 7,554 Shares of Danaher Corporation $DHR

Avalon Trust Co raised its stake in shares of Danaher Corporation (NYSE:DHR) by 11.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 74,960 shares of the conglomerate’s stock after purchasing an additional 7,554 shares during the period. Danaher accounts for 1.1% of Avalon Trust Co’s portfolio, making the stock its 23rd largest holding. Avalon Trust Co’s holdings in Danaher were worth $14,808,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Boyd Watterson Asset Management LLC OH grew its position in Danaher by 2.1% in the 2nd quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock worth $499,000 after purchasing an additional 51 shares during the last quarter. Worth Financial Advisory Group LLC increased its holdings in Danaher by 4.6% during the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after purchasing an additional 53 shares in the last quarter. 1834 Investment Advisors Co. grew its holdings in Danaher by 3.3% during the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock worth $342,000 after acquiring an additional 54 shares during the last quarter. Bruce G. Allen Investments LLC raised its position in Danaher by 13.1% in the 2nd quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock worth $92,000 after purchasing an additional 54 shares during the last quarter. Finally, Texas Bank & Trust Co boosted its holdings in Danaher by 1.6% in the second quarter. Texas Bank & Trust Co now owns 3,567 shares of the conglomerate’s stock valued at $705,000 after acquiring an additional 55 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the sale, the senior vice president owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. This represents a 66.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. This represents a 11.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 11.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on DHR. Rothschild Redb cut shares of Danaher from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 8th. Barclays increased their price objective on Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. JPMorgan Chase & Co. raised their price objective on Danaher from $260.00 to $270.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Deutsche Bank Aktiengesellschaft increased their price target on shares of Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. Finally, TD Cowen increased their price target on Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. Eighteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $243.39.

Danaher Stock Up 1.8%

NYSE DHR opened at $219.60 on Thursday. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The business has a fifty day moving average price of $204.76 and a two-hundred day moving average price of $200.77. The stock has a market capitalization of $155.11 billion, a PE ratio of 45.28, a PEG ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.71 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were paid a $0.32 dividend. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio is currently 26.39%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.